Digest Network Come funziona
Network
/
Società
Su
Non verificato

Sumitomo Pharma America, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

5 comunicati stampa

Guarda tutti i comunicati
30/07/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
15/06/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
10/06/2026
Industria
Oncologia
Salute
Management
Medicina - Varie
Farmaceutica
Biotecnologia
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
01/06/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
18/05/2026
Scienza
Terza età
Medicina - Varie
Biotecnologia
Salute
Vetrine/Shopping
Farmaceutica
Oncologia
Eventi
Industria
New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0